Legal & General Group Plc Has $69.48 Million Position in argenx SE (NASDAQ:ARGX)

Legal & General Group Plc grew its holdings in argenx SE (NASDAQ:ARGX) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,970 shares of the company’s stock after purchasing an additional 2,698 shares during the quarter. Legal & General Group Plc’s holdings in argenx were worth $69,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ARGX. Steward Partners Investment Advisory LLC lifted its stake in argenx by 5.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after buying an additional 20 shares during the period. SG Americas Securities LLC increased its stake in shares of argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after acquiring an additional 21 shares in the last quarter. Dynasty Wealth Management LLC lifted its position in shares of argenx by 3.4% during the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after acquiring an additional 22 shares during the period. Finally, Choreo LLC boosted its stake in argenx by 4.4% during the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock worth $342,000 after acquiring an additional 23 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Up 6.4 %

argenx stock opened at $580.94 on Friday. The firm has a 50 day moving average price of $607.87 and a 200-day moving average price of $603.90. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The company has a market capitalization of $35.30 billion, a P/E ratio of -660.16 and a beta of 0.60.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ARGX shares. Truist Financial reaffirmed a “buy” rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Oppenheimer boosted their target price on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $720.00 price target on shares of argenx in a report on Tuesday. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.